Arcturus Therapeutics (ARCT) to Release Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) will announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($1.85) by $1.21. The company had revenue of $49.86 million for the quarter, compared to the consensus estimate of $21.00 million. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. During the same period in the prior year, the firm posted ($1.98) EPS. On average, analysts expect Arcturus Therapeutics to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arcturus Therapeutics Stock Up 0.5 %

Shares of NASDAQ ARCT traded up $0.09 during midday trading on Tuesday, hitting $17.91. The stock had a trading volume of 199,073 shares, compared to its average volume of 465,359. The business’s 50 day moving average is $20.78 and its 200-day moving average is $24.44. Arcturus Therapeutics has a 52 week low of $17.26 and a 52 week high of $45.00. The company has a market cap of $482.32 million, a P/E ratio of -6.77 and a beta of 2.64.

Analyst Upgrades and Downgrades

ARCT has been the subject of a number of research analyst reports. Leerink Partners assumed coverage on Arcturus Therapeutics in a report on Monday, August 12th. They issued an “outperform” rating and a $70.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research report on Tuesday, October 1st. Leerink Partnrs raised shares of Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $71.40.

Insiders Place Their Bets

In other news, COO Pad Chivukula sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the transaction, the chief operating officer now owns 435,334 shares of the company’s stock, valued at $9,037,533.84. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 15.30% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.